ReviewWorld journal of clinical cases2021
Gastric neuroendocrine neoplasms: A review.
Review in World journal of clinical cases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The Association Between Proton Pump Inhibitor Use and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review.Journal of gastrointestinal cancer · 2025Pooled it
- Gastric carcinoid with metastasis to a regional lymph node in a dog: case report.The Journal of veterinary medical science · 2026Article
- Neuroendocrine Neoplasms of the Gastrointestinal Tract: Morphology, WHO 2022 Grading, and Prognostic Perspectives.Cureus · 2026Review
- Current Medical Controversies in Zollinger-Ellison Syndrome.Biomedicines · 2025Review
- Gastric Glomus Tumor with Neuroendocrine Features: A Diagnostic Pitfall for Neuroendocrine Tumors.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Gastroesophageal Neuroendocrine Tumors: Outcomes and Management.Journal of clinical medicine · 2025Review
- Multiple pseudoprogressions during ongoing immunotherapy-based treatment of advanced gastric neuroendocrine carcinoma: A case report and review of literature.World journal of gastrointestinal oncology · 2025Article
- A case of early-stage type 3 gastric neuroendocrine tumor in the upper body of the stomach: is endoscopic resection feasible?Clinical journal of gastroenterology · 2024Article
- Article
- Gastric Polyps Detected Incidentally during Gastroscopy and Follow-Up Results.Journal of clinical medicine · 2024Article
- Article
- Management of type 1 gastric neuroendocrine tumors: an 11-year retrospective single-center study.BMC gastroenterology · 2023Article
- Application of machine learning algorithms to predict lymph node metastasis in gastric neuroendocrine neoplasms.Heliyon · 2023Article
- Gastroenteropancreatic Neuroendocrine Tumors-Current Status and Advances in Diagnostic Imaging.Diagnostics (Basel, Switzerland) · 2023Review
- Detection of Neuroendocrine Tumours by Enteroscopy: A Case Report.Medicina (Kaunas, Lithuania) · 2023Article
- Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis.World journal of gastrointestinal oncology · 2023Article
- Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs.Cancers · 2023Review
- Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study.Biomedicines · 2023Article
- The Complex Histopathological and Immunohistochemical Spectrum of Neuroendocrine Tumors-An Overview of the Latest Classifications.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric neuroendocrine neoplasms (g-NENs) or neuroendocrine tumors are generally slow-growing tumors with increasing incidence. They arise from enterochromaffin like cells and are divided into four types according to clinical characteristic features. Type 1 and 2 are gastrin dependent, whereas type 3 and 4 are sporadic. The reason for hypergastrinemia is atrophic gastritis in type 1, and gastrin releasing tumor (gastrinoma) in type 2 g-NEN. The diagnosis of g-NENs needs histopathological investigation taken by upper gastrointestinal endoscopy. g-NENs are positively stained with chomogranin A and synaptophysin. Grading is made with mitotic index and ki-67 proliferation index on histopathological analysis. It is crucial to discriminate between types of g-NENs, because the management, treatment and prognosis differ significantly between subtypes. Treatment options for g-NENs include endoscopic resection, surgical resection with or without antrectomy, medical treatment with somatostatin analogues, netazepide or chemotherapy regimens. Follow-up without excision is another option in appropriate cases. The prognosis of type 1 and 2 g-NENs are good, whereas the prognosis of type 3 and 4 g-NENs are close to the prognosis of gastric adenocancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.